STOCKHOLM, June 19, 2017 /PRNewswire/ --
Nuevolution AB (publ) (NUE.ST) will participate in the BIO International Convention to be held in San Diego, 19-22 June, and will present new data on the company's bromodomain BET BD1 selective program.
Alex Haahr Gouliaev, CEO and Ton Berkien, CBO, will present new data from an eight-week study in a genetic mouse model of Lupus (Mrl-lpr). At age 12 weeks, these animals develop symptoms of Lupus. Twice daily oral treatment for eight weeks with Nuevolution's bromodomain BET BD1 selective inhibitor NUE7770, led to a dose-dependent reduction of auto-antibody production, a recognized and applied biomarker of the human disease, Systemic Lupus Erythematosus (SLE, or Lupus). Furthermore, the study showed that NUE7770 was well tolerated during the eight weeks of dosing.
Nuevolution will also promote its previously disclosed positive data on the efficacy of NUE7770 in the pristane-induced mouse model of Lupus, where auto-antibody production was also inhibited by NUE7770.
Nuevolution has now obtained positive results from two independent and different animal models of Lupus following oral dosing with one of its selective inhibitors. This strengthens the potential opportunity for treatment of Lupus in humans with a bromodomain BET BD1 selective inhibitor.
Nuevolution has already established a benign in vitro and in vivo safety profile for inhibition of the BD1 subtype of the BET bromodomain by NUE7770.
Earlier released data demonstrate a unique binding mechanism of Nuevolution's bromodomain BET BD1 selective compound series, and provide the project with a structural explanation for the BD1 selectivity. This important structural information is currently used to support Nuevolution's further optimization towards a candidate compound.
For more information, please contact:
Alex Haahr Gouliaev,
Henrik D. Simonsen,
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Monday 19 June 2017, 8:30 CET.
Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at: www.nuevolution.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nuevolution-presents-additional-positive-animal-results-in-lupus-from-its-bet-selective-program-300475671.html